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We report on four siblings with Cockayne-like syndrome with
thrombocytopenia and nephrotic syndrome. The parents were
healthy and consanguineous, consistent with an autosomal
recessive mode of disease inheritance. UV irradiation of fibro-
blasts revealed an intermediate sensitivity between normal and
standard Cockayne syndrome (CS) control cells. A genome-wide
linkage scan conducted using Affymetrix 10K arrays provided
exclusion of the known CS genes in the family, and evidence that
the disease gene maps to 1p33-p31.1. Thrombocytopenia has not
previously been linked with CS, but two patients with CS in
association with nephrotic syndrome have previously been
documented and the phenotypes are compared with the patients
described here. We suggest that this Cockayne-like phenotype
with thrombocytopenia and nephrotic syndrome may be a novel
DNA repair disorder, and propose that further investigation of
other affected families may help identify the causative genetic
defect.  2009 Wiley-Liss, Inc.
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INTRODUCTION
Cockayne syndrome (CS) is a rare autosomal recessive disorder
with variable expression. The phenotype classically becomes
evident in early childhood, and patients present with hyperpig-
mentation, sunken eyes secondary to subcutaneous lipoatrophy,
failure to thrive, short stature and microcephaly. Neurological
sequelae include progressive ataxia, global developmental delay,
sensorineural deafness and tremors [Cockayne, 1936; Nance and
Berry, 1992; Lehmann et al., 1993; Tan et al., 2005]. While approxi-
mately 10% of patients with CS develop renal pathology, this rarely
leads to serious complications [Hirooka et al., 1988; Sato et al., 1988;
Reiss et al., 1996]. Renal changes may vary significantly between
affected individuals but typically include tubulointerstitial inflam-
mation, interstitial fibrosis and tubular atrophy [Hirooka et al.,
1988; Funaki et al., 1996Q1]—all consistent with nonspecific end-stage
renal disease. A small simplified glomerular structure with wrin-
kling of the basement membrane appears to be specific to Cockayne
Syndrome [Funaki et al., 1996]. Thrombocytopenia has not, to our
knowledge, been reported previously in association with CS.
A diagnosis of CS is made on clinical features and can be
confirmed by UV irradiation of fibroblasts from the patient. CS
cells fail to restore normal levels of RNA synthesis following UV
irradiation when compared to control fibroblasts [Mayne and
Lehmann, 1982]. Mutations in genes CSA and CSB, coding for
proteins involved in transcription-coupled repair, are thought to be
responsible for the Cockayne phenotype in the majority of cases
[Lehmann, 2003]. There is poor genotype/ phenotype correlation
[Mallery et al., 1998], and identical mutations in CSB may be
associated with either CS or xeroderma pigmentosum (XP) - another
DNA repair disorder [Lehmann, 2003]. Mutations in genes XPB,
XPD, and XPG can result in a mixed clinical phenotype with
neurological features of CS and skin abnormalities associated with
XP [Lehmann, 2003].
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Here we report on four siblings affected by a Cockayne-like
disorder associated with nephrotic syndrome and thrombocytope-
nia, and an intermediate fibroblast response to UV irradiation.
CLINICAL REPORT
The parents of the four affected children are healthy, Pakistani first
cousins (Fig. 1). The two older siblings (III.1 and III.2) were first
referred for genetic evaluation aged 6 and 5, respectively. They
were noted to have a distinctive phenotype with severe global
developmental delay, short stature and similar dysmorphic fea-
tures: progeroid facies with microcephaly, frontal bossing, sunken
eyes, high nasal bridge and large, prominent, low-set ears. There was
no history of photosensitivity, poor vision or deafness.
Patient 1
The eldest sibling (III.1, Fig. 1) weighed 2.8 kg (9th centile) at birth.
At 6 years, OFC was 47.5 cm, height 93 cm, and weight 13.2 kg; all
well below the 0.4th centile. In addition to the dysmorphic features
he shared with his sister, he also had keratinized, purple, nodular
lesions on his forehead, the exact nature of which could not be
identified. Development was slowly progressive with no loss of
skills. At presentation, aged 6, he was able to walk up stairs with two
feet per step, draw a circle, had good pincer grip and had a few single
recognizable words. Previous diagnostic investigations had been
inconclusive. He was noted to have a normal karyotype. Comput-
erized tomography (CT) of his brain at the age of 2 revealed
‘‘moderately prominent ventricles and sulci’’ but was otherwise
normal with no evidence of basal ganglia calcification. Urine amino
acids were normal and congenital infection screen was negative. He
had further investigations at the age of 7, during admission to
hospital for steroid-unresponsive nephrotic syndrome. A renal
biopsy identified glomerular sclerosis, tubular atrophy, interstitial
fibrosis, and hyaline thickening of the arteriolar wall, consistent
with the non-specific end-stage renal pathology typically observed
in CS. The patient was thrombocytopenic on admission (platelet
count: 50 109/L) and had a history of easy bruising. A bone
marrow biopsy showed hypocellular particulate bone marrow with
representation of all three hematopoietic precursor cell lines in-
cluding erythrocytes, leucocytes, and thrombocytes. A blood smear
was normal except for a few spherocytes, consistent with mild
hemolysis. The hematological findings were reviewed and felt to be
consistent with a hereditary thrombocytopenia. Normal sensitivity
to diepoxybutane excluded Fanconi anemia. Generalized osteopo-
rosis and delayed bone age was apparent on skeletal survey.
Recovery of RNA synthesis following UV irradiation of skin
fibroblasts gave an intermediate result between normal and known
CS controls (Fig. 2). At the age of 8 he died secondary to compli-
cations of nephrotic syndrome.
Patient 2
The second child (III.2, Fig. 1) was born at 41 weeks by normal
vaginal delivery, weighing 3.1 kg (50th centile). The neonatal period
was complicated by hypotonia, and she required 2 days admission
to the Special Care Baby Unit. At presentation aged 5, OFC was
44.5 cm and length 87 cm. At age 7 all growth parameters were
below the 0.4th centile. Like her brother, this patient had slowly
progressive global developmental delay with no loss of skills. She
walked at 21 months, and by age 7 she had severe developmental
delay particularly affecting speech with only a few single words. A
skeletal survey revealed delayed bone age with non-specific changes.
Borderline growth hormone response was noted, and the patient
was started on replacement therapy at the age of 9. She subsequently
developed nodular lesions on her skin similar to those of her elder
brother and persistent thrombocytopenia. Normal sister chromatid
exchanges for Bloom syndrome, diepoxybutane sensitivity and
chromosomal ionizing radiation excluded Bloom syndrome,
ataxia telangiectasia and Fanconi anemia, respectively. Attempts
to establish a fibroblasts culture for UV sensitivity testing were
unsuccessful, and parents declined a second attempt. She developed
FIG. 1. Pedigree showing the four affected siblings (III.1, III.2, III.3, III.4) as filled black symbols. No other family members are known to be affected and
are represented as unfilled symbols. Circles denote females and squares denote males. Individuals of unknown gender are represented by a rhombus.
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steroid-responsive nephrotic syndrome aged 10, and died second-
ary to complications at the age of 16.
Patient 3
The third child (III.3, Fig. 1; Fig. 3a) was born at 42 weeks by
spontaneous vaginal delivery with no perinatal complications. Her
birth weight was 2.57 kg (0.4th centile) with a head circumference
also at the 0.4th centile. The patient was globally delayed from the
outset; she was able to sit alone by 1 year, crawled at 18 months,
walked at 21 months and had a vocabulary of five or six words by
29 months. Development was assessed at 29 months and although
the child was progressing, she had global developmental delay
corresponding to a corrected developmental age of 18 months.
There was no history of loss of skills. A karyotype was normal. CT
brain performed at the age of 2 was normal with no evidence of
intracranial calcification. By 14 months she had developed the
Cockayne-like facial features of her two older siblings including
sunken eyes, frontal bossing, large prominent low set ears, a high
nasal bridge and microcephaly, although she had not yet developed
any skin papules. Vision and hearing were normal and there was no
evidence of photosensitivity. She exhibited gross motor delay,
but otherwise appeared less severely affected than her siblings. UV
irradiation of fibroblasts again gave a response intermediate
between that of normal and CS cells, similar to her brother. Testing
for carbohydrate deficient glycoprotein syndrome revealed normal
transferrins. At the age of 6 she has developed persistent moderate
thrombocytopenia and proteinuria.
Patient 4
The youngest sibling (III.4, Fig. 1) had an uncomplicated delivery.
At birth his weight was 3.2 kg (25th centile) and head circumference
below the 9th centile. He sat at 10 months, walked at 18 months and
had a vocabulary of one word at 21 months. By the age of 25 months
he had mild global developmental delay corresponding to a devel-
opmental age of 18 months. There was no history of loss of skills.
The patient has similar dysmorphic features to his siblings
(Fig. 3b,c) and like his siblings, he has no evidence of photosensi-
tivity, visual problems or deafness. Although he appears to be
affected by the same condition as his three siblings he has not yet
developed nephrotic syndrome or thrombocytopenia.
LINKAGE ANALYSIS
The parents of these four affected siblings are consanguineous
indicating a likely autosomal recessive mode of inheritance. To
search for a disease locus a genome wide linkage scan of the parents
FIG. 2. Recovery of RNA synthesis following UV irradiation of skin fibroblasts from patient III.1. Pooled data from four experiments show an intermediate
result between normal and Cockayne syndrome controls.
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and all four siblings was conducted using GeneChip mapping 10K
Xba 142 Arrays according to manufacturers protocol (Affymmetrix
Inc., Santa Clara, CA). Segregation of SNP markers in accordance
with affected versus unaffected members of the family excluded the
possibility that the disease was caused by dominant or recessive
mutations in any of the known CS genes, CSA on chromosome 5,
CSB on chromosome 10, XPB on chromosome 2, XPD on chro-
mosome 19 and XPG on chromosome 13.
A 27 Mb interval of shared homozygosity was identified encom-
passing 104 informative SNPs (defined by dsSNPs rs2354462 to
rs718883) at chromosome 1p33-p31.1. Multipoint linkage analysis
assuming a fully penetrant autosomal recessive mode of inheritance
was undertaken using the GENEHUNTER program [Kruglyak
et al., 1995]. Allele frequencies for each marker were assumed to
be equal and a population disease gene frequency of 0.001 was used
to estimate the maximum LOD score. Statistical support for linkage
was evaluated over a range of marker allele frequencies. The map
order and distances between markers were based on the UCSC
Human Genome Browser (http://genome .ucsc.edu/). The multi-
point LOD score across the 27 Mb region of linkage was 2.4.
A contiguous gene syndrome cannot be excluded; but any such
deletion would have to be <170 kb in size, as genotype signatures
were obtained from 104 markers mapping to the region of linkage.
One hundred thirty-one transcripts map to the 27 Mb region of
linkage (UCSC Human Genome Browser, March 2006). Excluding
the predicted or hypothetical genes mapping to the region that have
little or no associated information regarding their biological func-
tion, there are no obvious candidate genes at present.
DISCUSSION
The four siblings described in this report have many of the classic
features associated with CS. However, some characteristic findings
are missing: they all have normal hearing and vision, no evidence of
sun-sensitivity or intracranial calcification on brain CT imaging. A
literature search did not reveal any other reports of CS in association
with thrombocytopenia. Two other children with a diagnosis of CS,
who have died as a result of nephrotic syndrome, have previously
been described [Reiss et al., 1996; Funaki et al., 2006]. In the report
by Reiss et al. [1996], there was a marginal hypersensitivity to sister
chromatid exchanges induced by UVC but not to those induced by
UVB. The report by Funaki et al. [2006] states that ‘‘she underwent a
skin biopsy that demonstrated ultraviolet-induced damage,’’ with-
out any data being presented. It is therefore difficult to assess the UV
sensitivity status of these patients’ cells.
It is striking that, in addition to having nephrotic syndrome, the
child reported by Reiss et al. [1996] was phenotypically very similar
to the children described in this report: he had many classic CS
features but did not have the typical photosensitive rash or deafness.
Nephrotic syndrome in this child was unresponsive to steroids
[Reiss et al., 1996], whereas the patient described by Funaki et al.
[2006] was treated with oral prednisolone with good effect. Table I
compares the phenotype of the siblings described in this report and
the other reported children with CS and nephrotic syndrome.
In this case report Patient 1 had steroid resistant nephrotic
syndrome, whilst Patient 2 was responsive to steroid treatment
and Patient 3 had persistent proteinuria. This may represent the
natural progression of renal pathology in this disorder with initial
proteinuria deteriorating into nephrotic syndrome. It may be that
the renal pathology seen in this family develops from steroid
responsive to steroid unresponsive nephropathy. Alternatively,
Patient 2 may have had a partial response to corticosteroid therapy
in the early stages of a developing resistant nephrosis.
The authors are aware of about 10 other patients where irradia-
tion of fibroblasts has produced an intermediate response of RNA
FIG. 3. a: Clinical pictures of Patient 3 at 3 years and 11 months. b,c:
Clinical pictures of Patient 4 at 1 year and 6 months. The images
demonstrate the phenotype: sunken eyes, frontal bossing, low-set
ears and microcephaly. Informed consent was obtained for
publication of these pictures. [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.com]
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synthesis recovery following UV irradiation (A.R. Lehmann, un-
published work). Limited information exists regarding phenotype
and results of molecular diagnostic testing in these patients. At least
three of the patients appear to have a clear Cockayne-like pheno-
type. However, none are known to have developed nephrotic
syndrome.
Collectively these data suggest that the CS-like phenotype we
have identified in four affected individuals from a single family
represents a distinctive syndrome, possibly a consequence of a novel
DNA repair disorder. As the parents of the patients we report were
consanguineous, autosomal recessive inheritance is most likely,
though other modes of transmission, including mitochondrial
inheritance, remain a possibility. On the basis of linkage data it
appears that the disease gene maps to 1p. Investigation of additional
affected families should, as well as further elucidate this emerging
phenotype, facilitate identification of the causal gene.
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TABLE I. Phenotype Comparison Between Classic CS, Children Described in the Literature With CS and Nephrotic Syndrome, and the Patients
Described in This Report
Cockayne
syndrome
Patient
reported
by Reiss
et al. [1996]
Patient
reported
by Funaki
et al. [2006] III.1 III.2 III.3 III.4
Developmental delay þ þ þ þ þ þ þ
Hyperpigmentation þ þ þ þ þ  
Loss of subcutaneous
tissue around the eye
þ þ þ þ þ þ þ
Microcephaly þ þ þ þ þ þ þ
Small stature þ þ þ þ þ þ þ
Peripheral neuropathy þ  þ    
Optic abnormalities þ  þ    
Deafness þ      
Nephrotic syndrome  þ þ þ þ þ 
Sun-sensitive rash þ  þ Late onset Late onset  
Response to UV irradiation Confirms Possible increase
in sister chromatic
exchange
Ambiguous Intermediate
RNA repair
Not done Intermediate
RNA repair
Not
done
Age at death Mean 12.3 (5) 6 12 7 16 Alive Alive
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